Latest Blogs

Guest Commentary
Nov 28, 2023
Women Mentoring Women: A Thank You Note to My Two Heroes
Dr. Tara Rajendran honors two women who, through their kindness and thoughtful attention, shaped her professional path from an early age.
Linda R. Duska, MD, MPH
Nov 20, 2023
The Potential of AI in Clinical Research
"We all need to stay informed and engaged on the topic of AI in order to be the best advocates for ourselves, our profession, and our patients."
International Perspectives
Nov 03, 2023
Cancer, Conflict, and Catastrophe: A Cry for Help From Sudan, a Country at War
Millions of people have been affected by the war in Sudan, and the outlook for patients with cancer is particularly dire. Dr. Nabeeha Karadawi, Dr. Salma Awad Elkareem Ali Mohamed, and Nagham Ali outline the current situation and call for immediate international aid.
Abdul-Rahman Jazieh, MD, MPH
Oct 24, 2023
Should Oncologists Continue to Be Ambivalent About Dietary Supplement Use by Their Patients?
If we believe that dietary supplements are active compounds—and many are—then we should deal with them as medications and advise our patients accordingly.
Subscribe to this column

Clifford A. Hudis, MD, FASCO, FACP

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

May 20, 2019
The Impact of Utilization Management on Patients and Practices: A Conversation with Dr. Jeffery Ward
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Exclusive Interview: NCI Director Dr. Ned Sharpless Discusses the Future of Cancer Clinical Trials
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Mar 11, 2019
Losing a Board Member: 5 Lessons From the Life of Dr. Arti Hurria
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Feb 07, 2019
Exclusive Interview: FDA Commissioner Dr. Scott Gottlieb Talks Drug Pricing, Expanded Access, and Tobacco Control
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Feb 01, 2019
Reflections on World Cancer Day 2019: The Challenge of “I Will”
What will each of us do, going forward, to further confront and reduce the global burden of cancer? For us at ASCO, the challenge will be answered through our mission pillars: education, research, and quality.
Jan 28, 2019
What You Need to Know About the Final 2019 Medicare Physician Fee Schedule and Quality Payment Program Rule
Editor’s note: Dr. Hudis hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity.

Pages